Neuland Laboratories

Neuland Laboratories Financial Leverage

The Financial Leverage (Equity Multiplier) of Neuland Laboratories (NEULANDLAB.NS) as of Oct 31, 2026 is 1.56. In the previous year, Financial Leverage (Equity Multiplier) was 1.43 — a change of 9.34% (higher).

Financial Leverage

1.56

YoY

9.34%

Last updated:

Financial Leverage (Equity Multiplier) of Neuland Laboratories is 2026 1.56 . Financial Leverage (Equity Multiplier) of Neuland Laboratories was 2025 1.43 . It decreases by 9.34% higher compared to the previous year.

The Neuland Laboratories Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.62 INR
Jan 1, 2020
1.73 INR
Jan 1, 2021
1.68 INR
Jan 1, 2022
1.65 INR
Jan 1, 2023
1.59 INR
Jan 1, 2024
1.43 INR
Jan 1, 2025
1.43 INR
Jan 1, 2026
1.56 INR
The Neuland Laboratories Financial Leverage history
YEARFinancial LeverageYoY
1.56+9.34%
1.43+0.07%
1.43-10.10%
1.59-3.46%
1.65-2.28%
1.68-2.85%
1.73+7.27%
1.62-15.81%
1.92+18.29%
1.62-42.20%
2.81-11.42%
3.17-18.71%
3.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Financial Leverage (Equity Multiplier) of Neuland Laboratories is 1.56 in 2026.

Financial Leverage (Equity Multiplier) of Neuland Laboratories changed from 1.43 to 1.56, representing a 9.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Neuland Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Neuland Laboratories

All Key Metrics — Neuland Laboratories